Relmada Therapeutics, Inc. Common Stock (RLMD) Stock
NASDAQ · RLMD
Key stats
- Market cap
- $472.55M
- Price / Earnings ratio
- -7.4x
- EPS (TTM)
- -$0.92
- Volume
- Loading
- 52-week high
- $8.00
- 52-week low
- $2.97
Source: third-party data provider, as of November 13, 2026
Compare with RLMD
Recent news

Zacks Investment Research
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
PositiveRLMDSeptember 14, 2026
Zacks Investment ResearchPositive
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
RLMD

Zacks Investment Research
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
NegativeRLMDAugust 31, 2026
Zacks Investment ResearchNegative
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
RLMD

Zacks Investment Research
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
PositiveRLMDAugust 25, 2026
Zacks Investment ResearchPositive
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
RLMD

Zacks Investment Research
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
RLMDAugust 11, 2026
Zacks Investment Research
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
RLMD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 66.17
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.04
- MACD histogram
- 0.12
- SMA 50
- $3.78
- Price above SMA 50
- EMA 50
- $3.93
- Price above EMA 50
- SMA 200
- $5.36
- Price below SMA 200
- EMA 200
- $4.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
268M177M88M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-57.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
PositiveRLMDSeptember 14, 2026
Zacks Investment ResearchPositive
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
RLMD

Zacks Investment Research
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
NegativeRLMDAugust 31, 2026
Zacks Investment ResearchNegative
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
RLMD

Zacks Investment Research
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
PositiveRLMDAugust 25, 2026
Zacks Investment ResearchPositive
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
RLMD

Zacks Investment Research
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
RLMDAugust 11, 2026
Zacks Investment Research
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
RLMD

MarketBeat
Relmada Therapeutics Q2 Earnings Call Highlights
RLMDAugust 7, 2026
MarketBeat
Relmada Therapeutics Q2 Earnings Call Highlights
RLMD

MarketBeat
Relmada Therapeutics Q1 Earnings Call Highlights
RLMDMay 13, 2026
MarketBeat
Relmada Therapeutics Q1 Earnings Call Highlights
RLMD

Zacks Investment Research
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
RLMDApril 13, 2026
Zacks Investment Research
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
RLMD

Zacks Investment Research
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
RLMDApril 2, 2026
Zacks Investment Research
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
RLMD

Zacks Investment Research
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
RLMDMarch 26, 2026
Zacks Investment Research
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
RLMD

Zacks Investment Research
RLMD Stock Surges 42% in a Week: Here's What You Should Know
RLMDMarch 12, 2026
Zacks Investment Research
RLMD Stock Surges 42% in a Week: Here's What You Should Know
RLMD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Relmada Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees17
CEODr. Sergio Traversa M.B.A., Pharm.D.
IPO DateOct 10, 2019
HeadquartersCoral Gables, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 1960 |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 1964 |
| Mr. Paul E. Kelly M.B.A. | COO & Director | 1957 |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 1965 |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | — |
Fundamentals
Valuation
Price-to-book value2.21
Profitability
Return on Equity-48.00%
Return on Assets-44.00%
EBITDA$-61.93M
Trading
Average volume1,641,436
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 66.17
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.04
- MACD histogram
- 0.12
- SMA 50
- $3.78
- Price above SMA 50
- EMA 50
- $3.93
- Price above EMA 50
- SMA 200
- $5.36
- Price below SMA 200
- EMA 200
- $4.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -21.3 | +31.7 | ||||||||||
| 2022 | -22.3 | +12.1 | +33.3 | -14.6 | -27.4 | +5.3 | +39.9 | +18.2 | +23.4 | -82.0 | -28.6 | -24.1 |
| 2023 | +20.8 | -16.3 | -32.7 | +6.3 | +4.4 | -9.6 | +3.6 | +32.0 | -20.8 | -2.0 | -17.1 | +64.9 |
| 2024 | -10.1 | +34.4 | -31.6 | -25.4 | -18.7 | -2.6 | +19.2 | -24.1 | +18.2 | +6.4 | -13.5 | -84.2 |
| 2025 | -22.2 | -23.5 | +3.8 | +18.5 | +114.3 | -15.5 | +0.0 | +89.8 | +41.5 | +4.6 | +105.0 | +9.3 |
| 2026 | -18.8 | +19.1 | +43.8 | +5.9 | -5.6 | +1.0 | -16.9 | -17.7 | -15.5 | -2.2 | +15.4 |
Compare stocks
Market cap
$472.55M
-
-
-
Price / Earnings ratio
-7.40
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,641,436
-
-
-
Earnings per share
$-0.92
-
-
-



